All posts

HEXO is trading at a big discount to its cannabis peers, Beacon Securities says

With the recent harvesting of its first crop from the company’s new one million square foot greenhouse, HEXO (HEXO Stock Quote, Chart TSX:HEXO) has reinforced its position as a major cannabis producer, according to Beacon Securities analyst Russell Stanley, who in a note to clients on Monday maintained his “Buy” rating and $14.00 target.

HEXO Corp on Monday announced the first harvest at its Building 9 expansion in Gatineau, Quebec, with CEO and co-founder Sébastien St-Louis stating that it showcases the company’s dedication and commitment.

“We are very proud of our continued ability to execute on our plans, creating value for our shareholders and demonstrating our commitment to our customers,” St-Louis said in a press release. “This cultivation milestone means that an expanded HEXO product offering will be available to more Canadians shortly.”

Stanley says, “We view this milestone positively as the expanded capacity allows HEXO to expand its shelf space penetration with provincial buyers, building on its position as the largest supplier in Quebec. Plants had been moving into the greenhouse since January, and the company will continue to ramp up to its full annualized capacity of 108,000 kg.”

The analyst estimates that HEXO now trades at a 60 per cent discount to the 36x average among cannabis companies with a $1 billion-plus market cap and at a 76 per cent discount to its US-listed peers. He notes the company’s net revenue guidance provided last month ($450 million in fiscal 2020) with its second quarter financials, saying, “We believe this demonstrates management’s high level of conviction in its sales outlook, particularly given how extremely rare formal revenue guidance is in this industry.”

For upcoming catalysts, Stanley refers to the closing of HEXO’s acquisition of Newstrike Brands, additional partnership and/or product development news and the company’s third quarter results due in June. His $14.00 target represents a projected return of 37 per cent at the time of publication.

Tagged with: hexo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Cannara Biotech is a buy, Research Capital says

Research Capital analyst Greg McLeish said in a July 29 update that Cannara Biotech (Cannara Biotech Stock Quote, Chart, News,… [Read More]

54 minutes ago

Ahead of Q2 results, is Tantalus Systems a buy?

Beacon Securities analyst Gabriel Leung noted in a July 30 report that Tantalus Systems (Tantalus Systems Holding Stock Quote, Chart,… [Read More]

1 hour ago

Sanuwave Health is a buy, Roth Capital says

Roth Capital Markets is initiating coverage of Sanuwave Health (Sanuwave Health Stock Quote, Chart, News, Analysts, Financials NASDAQ:SNWV) with a… [Read More]

2 hours ago

Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in… [Read More]

2 hours ago

Nextracker wins price target raise at Roth

Roth Capital Markets analyst Philip Shen said in a July 28 earnings preview that Nextracker (Nextracker Stock Quote, Chart, News,… [Read More]

2 hours ago

Telus is my top telecom stock, Brian Madden says

Brian Madden, Chief Investment Officer at First Avenue Investment Counsel, said on BNN Bloomberg’s Market Call on July 25 that… [Read More]

23 hours ago